Besser Lilah M, Crary John F, Mock Charles, Kukull Walter A
From the National Alzheimer's Coordinating Center (L.M.B., C.M., W.A.K.), Department of Epidemiology, University of Washington, Seattle; and Department of Pathology (J.F.C.), Fishberg Department of Neuroscience, Friedman Brain Institute, Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY.
Neurology. 2017 Oct 17;89(16):1707-1715. doi: 10.1212/WNL.0000000000004521. Epub 2017 Sep 15.
To conduct a clinicopathologic study to characterize clinical and neuropathologic features associated with cognitive impairment in participants with no neuritic amyloid plaques (primary age-related tauopathy [PART] definite) and sparse neuritic plaques (amyloid sparse).
Using the National Alzheimer's Coordinating Center database, we identified 377 individuals who were PART definite (n = 170) or amyloid sparse (n = 207), clinically examined within 1 year of death, and autopsied at 1 of 26 National Institute on Aging-funded Alzheimer's Disease Centers. Factors associated with the odds of being symptomatic (global Clinical Dementia Rating [CDR] score >0) were identified with multivariable logistic regression.
PART-definite participants less often had a high Braak neurofibrillary tangle stage V or VI (4%) compared to amyloid sparse participants (28%, < 0.001). Of the PART-definite participants, 98 were symptomatic and 72 asymptomatic according to their global CDR scores. PART-definite participants were less often symptomatic (58%) compared with amyloid sparse participants (80%, < 0.001). Within the PART-definite group, independent predictors of symptomatic status included depression (adjusted odds ratio [aOR] 4.20, 95% confidence interval [CI] 2.15-8.19), Braak stage (aOR 1.42, 95% CI 1.04-1.95), and history of stroke (aOR 8.09, 95% CI 2.63-24.82). Within the amyloid sparse group, independent predictors of symptomatic status included education (aOR 0.80, 95% CI 0.65-0.99), Braak stage (aOR 1.91, 95% CI 1.07-3.43), and amyloid angiopathy (aOR 2.75, 95% CI 1.14-6.64).
These findings support the hypothesis that participants with PART have an amyloid-independent dementing Alzheimer disease-like temporal lobe tauopathy.
开展一项临床病理研究,以描述在无神经炎性淀粉样斑块(确诊的原发性年龄相关性tau病[PART])和神经炎性斑块稀疏(淀粉样蛋白稀疏)的参与者中与认知障碍相关的临床和神经病理特征。
利用国家阿尔茨海默病协调中心数据库,我们识别出377名个体,他们是确诊的PART(n = 170)或淀粉样蛋白稀疏(n = 207),在死亡前1年内接受了临床检查,并在26个由美国国立衰老研究所资助的阿尔茨海默病中心之一进行了尸检。通过多变量逻辑回归确定与出现症状(总体临床痴呆评定量表[CDR]评分>0)几率相关的因素。
与淀粉样蛋白稀疏的参与者(28%,P<0.001)相比,确诊的PART参与者处于Braak神经原纤维缠结V期或VI期的比例较低(4%)。在确诊的PART参与者中,根据其总体CDR评分,98名有症状,72名无症状。与淀粉样蛋白稀疏的参与者(80%,P<0.001)相比,确诊的PART参与者出现症状的比例较低(58%)。在确诊的PART组中,症状状态的独立预测因素包括抑郁(调整后的优势比[aOR] 4.20,95%置信区间[CI] 2.15 - 8.19)、Braak分期(aOR 1.42,95% CI 1.04 - 1.95)和中风病史(aOR 8.09,95% CI 2.63 - 24.82)。在淀粉样蛋白稀疏组中,症状状态的独立预测因素包括教育程度(aOR 0.80,95% CI 0.65 - 0.99)、Braak分期(aOR 1.91,95% CI 1.07 - 3.43)和淀粉样血管病(aOR 2.75,95% CI 1.14 - 6.64)。
这些发现支持了这样一种假说,即PART参与者患有与淀粉样蛋白无关的、类似阿尔茨海默病的颞叶tau病导致的痴呆。